Showing 3971-3980 of 10444 results for "".
Trends in the Medical Aesthetic Market
https://practicaldermatology.com/series/c-suite-chats/trends-in-the-medical-aesthetic-market/24560/Ethan Min, CEO of Benev, discusses trends in the medical aesthetic market, including the potential impact that Glucagon-like peptide-1 (GLP-1) for weight loss will have on the aesthetics industry.The Emergence of Targeted Therapies for Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/the-emergence-of-targeted-therapies-for-prurigo-nodularis/48775/Christopher Bunick, MD, FAAD, discusses the importance of acknowledging prurigo nodularis as a distinct disease with its own molecular and transcriptomic features distinguishing it from atopic dermatitis, and how targeting the IL-31 receptor can change the game.DERM2020 Exhibitor Reaction: Brett Fair, EPI Health
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-exhibitor-reaction-brett-fair-epi-health/19847/Brett Fair of EPI Health, a DERM2020 exhibitor, tells us what he thinks of the new virtual meeting world and how DEF is dominating it for dermatology!FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuQuarantine Quorum: Circling the Wagons
https://practicaldermatology.com/topics/practice-management/quarantine-quorum-circling-the-wagons/18180/With Quarantine Quorum, host Neal Bahtia, MD provides a diary of life during the COVID-19 pandemic, talking to members of the dermatology community as they adapt to ongoing changes in their personal and private lives. In this edition, Hilary Baldwin, MD; Adam J. Friedman, MD; Mark Kaufmann, MD; andCOVID-19 Impact: iPledge and Isotretinoin Prescribing
https://practicaldermatology.com/topics/acne-rosacea/covid-19-impact-ipledge-and-isotretinoin-prescribing/19763/For patients on isotretinoin, complying with the iPledge program while treating patients virtually can be challenging. Joshua Zeichner, MD discusses new FDA guidance that allows female patients to take OTC pregnancy tests in order to continue treatment. He also discusses when patients do and do notTaking “picture perfect” before and after photos
https://practicaldermatology.com/topics/practice-management/taking-picture-perfect-before-and-after-photos/19751/You probably know the importance of including before and after photos on your dermatology website. However, you might be wondering how to create a professional looking image gallery without a photographer on call. Check out the latest video from Ekwa Marketing to find out!Practical Dermatology March 2026: Page-Turner Format
https://practicaldermatology.com/issues/march-2026/practical-dermatology-march-2026-page-turner-format/56412/Patient Perspectives on Unmet Needs in Topical Psoriasis Therapy
https://practicaldermatology.com/issues/january-february-2025/patient-perspectives-on-unmet-needs-in-topical-psoriasis-therapy/32972/Despite the advantages of topical treatment, nonadherence (including overuse and underuse) affects up to 50% of patients, and therapy overuse is often incited by the desire for rapid clearance, ineffectiveness, and unclear instructions.Eyes Have It: Bloodless Blephs and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/eyes-have-it-bloodless-blephs-and-more/18728/Demand for treatments around the eye continue to grow; patients want big results but little downtime. Dr. Niamtu discusses his "bloodless bleph" and other uses for fillers and toxins.